MD207C2 - Method of steroid derivatives preparation - Google Patents

Method of steroid derivatives preparation

Info

Publication number
MD207C2
MD207C2 MD94-0265A MD940265A MD207C2 MD 207 C2 MD207 C2 MD 207C2 MD 940265 A MD940265 A MD 940265A MD 207 C2 MD207 C2 MD 207C2
Authority
MD
Moldova
Prior art keywords
group
alkyl
oxydired
alkenyl
substituted
Prior art date
Application number
MD94-0265A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD207B1 (en
Inventor
Jean Georges Teutsch
Germain Costerousse
Daniel Philibert
Roger Deraedt
Original Assignee
Roussel Uclaf, Societe Anonyme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf, Societe Anonyme filed Critical Roussel Uclaf, Societe Anonyme
Publication of MD207B1 publication Critical patent/MD207B1/en
Publication of MD207C2 publication Critical patent/MD207C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention has relation to the steroid derivatives, especially, to the compound of general formula (I)in which R1 represents-N-(C1-C4)-alkyl dihydraindolyl, pyridinyl, phenyl, substituted by di(C1-C4)-alkylaminogroup or by di-(C1-C4)-alkyl group (in which nitrogen may be oxydired), by pyrollidin, di-(C1-C4)-alkylamino-(C1-C4)-alkylaky-or trimetil sylyl group;R2 - CH3, C2H5; R3-OH, CH3O, ethinyl, carbonyl, -C-NOH;R4-H, (C2-C4)-alkenyl, (C3-C6)-alkaden (C2-C6)-alkinyl (may be substituted by halogen, C6H5,(CH3)3 SI, lowert alkenyl); B and C form double bond or epoxy group, which have pharmocological valuable properties.The purpose of invention is creation of new substances with indis tinctive activity for given class.Synthesis is lead from corresponding ketal (A-ketal group, which may be cyclic or noncyclic), which is degradated by cationexchanged sulforesin or Hcl. The obtaining product incase of necesity is treated by hydroxylamine or if R1-di (C1-C4)-alkyl-amino-(C1-C4)-alkylphenyl, is oxydized for example metafluorineoxobenzoic acid with obtaining of substance of special destination, containing group, oxydired in nitrogen position and 9,10-epoxygroup.The new substances manifest the pronounced affinity as regards glucokorticosteroid and progestogenic receptor in the absence of the activity on the mineralkortikoid and estrogenic receptor having toxicity 100mg/kg of DL50.
MD94-0265A 1981-01-09 1994-08-08 Method of steroid derivatives preparation MD207C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8100272A FR2497807A1 (en) 1981-01-09 1981-01-09 NEW STEROID DERIVATIVES SUBSTITUTES IN 11B, THEIR PREPARATION PROCEDURE AND THEIR APPLICATION AS A MEDICINAL PRODUCT
SU823378150A SU1447289A3 (en) 1981-01-09 1982-01-08 Method of producing derivatives of steroids

Publications (2)

Publication Number Publication Date
MD207B1 MD207B1 (en) 1995-05-31
MD207C2 true MD207C2 (en) 1995-12-31

Family

ID=9253984

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0265A MD207C2 (en) 1981-01-09 1994-08-08 Method of steroid derivatives preparation

Country Status (22)

Country Link
US (4) US4386085A (en)
EP (1) EP0057115B1 (en)
JP (2) JPS57168000A (en)
KR (1) KR870001936B1 (en)
AU (2) AU550334B2 (en)
BG (1) BG60768B2 (en)
CA (1) CA1193246A (en)
DE (2) DE3262580D1 (en)
DK (1) DK166680B1 (en)
ES (2) ES8305786A1 (en)
FI (1) FI77872C (en)
FR (1) FR2497807A1 (en)
GE (1) GEP19960479B (en)
HU (1) HU185158B (en)
IE (1) IE52595B1 (en)
LT (1) LT2618B (en)
MD (1) MD207C2 (en)
NL (1) NL300001I2 (en)
PT (1) PT74263A (en)
SG (1) SG45987G (en)
SU (1) SU1447289A3 (en)
ZA (1) ZA8231B (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (en) 1982-06-11 1985-07-19 Roussel Uclaf NOVEL 19-NOR STEROIDS SUBSTITUTED IN 11B AND POSSIBLY IN 2, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS A MEDICAMENT
US4978657A (en) * 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2522328B1 (en) * 1982-03-01 1986-02-14 Roussel Uclaf NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR2640977A2 (en) * 1982-06-11 1990-06-29 Roussel Uclaf New position-11 substituted 19-norsteroids and their application as medicinal products.
DE3231828A1 (en) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 17 alpha -Alkynyl-3,3-alkylenedioxy-5 alpha ,10 alpha -epoxy-9(11)-oestren-17 beta -ol derivatives, process for the preparation thereof and the use thereof for further processing
DE3231827A1 (en) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11SS-ARYL-17 (ALPHA) -ALKINYL-17SS-HYDROXY-4.9 (10) - ESTRADIEN-3-ON DERIVATIVES, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3306121A1 (en) * 1983-02-18 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen 11 beta -Arylspirolactones in the steroid series, process for the preparation thereof and pharmaceutical products containing these compounds
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
DE3320580A1 (en) * 1983-06-03 1984-12-06 Schering AG, 1000 Berlin und 4709 Bergkamen D-HOMO-4,9,16-ESTRATRIENE, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
NO162241C (en) * 1983-06-14 1989-11-29 Roussel Uclaf NEW RADIOACTIVE ESTRADIA DERIVATIVES LABELED WITH JOD125, THE PROCEDURE OF THEIR PREPARATION AND THEIR USE OF RADIO DIMMUNOLOGICAL RESEARCH AND QUANTITY DETERMINATION OF STEROIDS IN BIOLOGICAL LIQUIDS.
FR2549067B1 (en) * 1983-06-14 1985-12-27 Roussel Uclaf TRITIUM-MARKED RADIOACTIVE ESTRADIAN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION FOR THE STUDY AND RADIO-IMMUNOLOGICAL ASSAY OF STEROIDS IN BIOLOGICAL FLUIDS
FR2548192B1 (en) * 1983-06-20 1985-11-22 Roussel Uclaf IODINE-MARKED RADIOACTIVE ESTRADIAN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO RADIOIMMUNOLOGICAL ASSAYS
DE3446661A1 (en) * 1984-12-18 1986-06-19 Schering AG, 1000 Berlin und 4709 Bergkamen NEW 13 (ALPHA) -ALKYL-17 (BETA) - (3-ACYLOXYPROPYL) GONANA
ES533260A0 (en) * 1983-06-15 1985-02-01 Schering Ag PROCEDURE FOR THE PREPARATION OF 13A-ALQUILGONANOS
IT1212835B (en) * 1983-08-18 1989-11-30 Lehner Ag BILIARY ACID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS.
DE3337450A1 (en) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
DE3347126A1 (en) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11SS-ARYL-ESTRADIENE, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
FR2566779B2 (en) * 1984-06-29 1987-03-06 Roussel Uclaf NOVEL 11B SUBSTITUTED STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US5116830A (en) * 1984-08-17 1992-05-26 Sri International Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
DE3438500C1 (en) * 1984-10-18 1986-05-28 Schering AG, 1000 Berlin und 4709 Bergkamen Process for the preparation of 11 beta -substituted DELTA <9>-19-norsteroids
FR2573657B1 (en) * 1984-11-29 1989-05-12 Roussel Uclaf PRODUCT COMPRISING AN ANTIPROGESTOMIMETIC SUBSTANCE AND A UTEROTONIC SUBSTANCE
DE3504421A1 (en) * 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen 11 beta -Phenylgonanes, the preparation thereof and pharmaceutical products containing these
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (en) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11SS-N, N-DIMETHYLAMINOPHENYL ESTRADIENE, THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids
DE3531903A1 (en) * 1985-09-05 1987-03-12 Schering Ag OXYTOCIN AND ANTI-DAYS FOR THE INTRODUCTION OF BIRTH OR ON THE THERAPEUTIC STOP OF GRAVIDITY
DE3533175A1 (en) * 1985-09-13 1987-03-19 Schering Ag ANTIGESTAGES TO SHIFT ENDOMETRIAL MATURATION
FR2596395B1 (en) * 1986-03-26 1989-05-26 Roussel Uclaf NOVEL STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
FR2598421B1 (en) * 1986-05-06 1988-08-19 Roussel Uclaf NOVEL 19-NOR OR 19-NOR D-HOMO STEROIDS SUBSTITUTED IN POSITION 11B BY A RADICAL PHENYL CARRYING AN ALKYNYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
DE3761308D1 (en) * 1986-07-23 1990-02-08 Akzo Nv 18-PHENYLESTRANE DERIVATIVES.
DE3625315A1 (en) * 1986-07-25 1988-01-28 Schering Ag 11SS- (4-ISOPROPENYLPHENYL) -ESTRA-4,9-DIENES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3708942A1 (en) * 1987-03-18 1988-09-29 Schering Ag 19.11SS-BRIDGED STEROIDS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3866410D1 (en) * 1987-04-24 1992-01-09 Akzo Nv 11-ARYLESTRANDERIVATIVES AND 11-ARYLPREGNANDERIVATIVES.
JPH085909B2 (en) * 1987-07-24 1996-01-24 協和醗酵工業株式会社 UCY1003 derivative
FR2618783B1 (en) * 1987-07-30 1991-02-01 Roussel Uclaf NOVEL 17-ARYL STEROIDS, THEIR PROCESSES AND INTERMEDIATES AS A MEDICAMENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
ES2053714T3 (en) * 1987-12-12 1994-08-01 Akzo Nv PROCESS FOR THE PREPARATION OF 11-ARILESTEROIDES.
BE1004905A4 (en) * 1987-12-30 1993-02-23 Roussel Uclaf NOVEL 17BETA-OH 19-NOR DERIVATIVES SUBSTITUTED IN 17ALPHA, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (en) * 1988-07-01 1990-01-04 Schering Ag 13-ALKYL-11SS-PHENYLGONANE
DE3832303A1 (en) * 1988-09-20 1990-04-12 Schering Ag 11SS-PHENYL-14SSH STEROIDS
FR2643638B1 (en) * 1989-02-24 1991-06-14 Roussel Uclaf NOVEL 19-NOR STEROIDS HAVING IN THE 11BETA POSITION A CARBON CHAIN COMPRISING AN AMIDE OR CARBAMATE FUNCTION, THEIR PREPARATION METHOD AND INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE3917274A1 (en) * 1989-05-24 1990-11-29 Schering Ag 9 (ALPHA) -HYDROXY-19, 11 (BETA) -BRIDGED STEROIDS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE3921059A1 (en) * 1989-06-23 1991-01-10 Schering Ag 11 (BETA) -ARYL-4-ESTRENE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651435A1 (en) * 1989-09-07 1991-03-08 Roussel Uclaf NEW USE OF ANTI-PROGESTOMIMETIC COMPOUNDS.
FR2654337B1 (en) * 1989-11-15 1994-08-05 Roussel Uclaf NOVEL BIODEGRADABLE INJECTABLE MICROSPHERES PREPARATION METHOD AND INJECTABLE SUSPENSIONS CONTAINING THEM.
FR2659233B1 (en) * 1990-03-06 1994-01-21 Roussel Uclaf NEW USE OF ANTI-PROGESTOMIMETIC COMPOUNDS IN FARMING ANIMALS.
DE4018168A1 (en) * 1990-06-01 1991-12-05 Schering Ag INITIAL CONNECTIONS FOR THE PRODUCTION OF 10SS-H STEROIDS AND A METHOD FOR THE PRODUCTION OF THESE OUTPUT CONNECTIONS
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
JPH0464052U (en) * 1990-10-05 1992-06-01
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
WO1995017192A1 (en) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
FR2718354B1 (en) * 1994-04-08 1996-05-03 Roussel Uclaf Application of the anti-glucocorticoid compounds for the preparation of medicaments intended for the prevention or the treatment of the manifestations linked to the narcotic withdrawal syndrome and the compositions containing them.
DE4415590A1 (en) * 1994-04-28 1995-11-02 Schering Ag Process for the stereoselective introduction of an alkynyl side chain to 11β-aryl-substituted 13alpha-alkylgonan-17-ones
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
EP0683172B1 (en) * 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv 11-(substituted phenyl)-estra-4,9-diene derivatives, their preparation and pharmaceutical compositions containing them
CA2253673C (en) 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE19706061A1 (en) * 1997-02-07 1998-08-13 Schering Ag Anti-gestagen effective steroids with fluorinated 17alpha alkyl chain
DE19745085A1 (en) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11β-Benzaldoxim-9alpha, 10alpha-epoxy-estr-4-ene derivatives, processes for their preparation and pharmaceutical preparations containing these compounds
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
ATE317699T1 (en) * 1998-05-15 2006-03-15 Univ Leland Stanford Junior GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEMENTIA
ATE473759T1 (en) 1998-05-22 2010-07-15 Univ Leland Stanford Junior BIFUNCTIONAL MOLECULES AND THERAPIES BASED THERAPIES.
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999066915A2 (en) 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
US20020169205A1 (en) * 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
CN1117759C (en) * 1999-09-02 2003-08-13 上海中西药业股份有限公司 Steroid and its preparation method, medicine composition and application
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
FR2826004B1 (en) * 2001-06-13 2008-03-28 Aventis Pharma Sa PROCESS FOR THE PREPARATION OF ESTROGENIC DERIVATIVES
EP1285927A3 (en) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Use of glucocorticoid antagonists for the prevention and treatment of diseases of the male reproductive system
US7326697B2 (en) 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
DE10221034A1 (en) 2002-05-03 2003-11-20 Schering Ag New 17-alpha-fluoroalkyl-11-beta-benzaldoxime-estradiene derivatives, useful as antigestagens in post-menopausal hormone replacement therapy or for treating e.g. gynecological disorders
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
FR2850022B1 (en) * 2003-01-22 2006-09-08 Centre Nat Rech Scient NOVEL USE OF MIFEPRISTONE AND ITS DERIVATIVES AS MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATH AND ITS APPLICATIONS
EP1613640A4 (en) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv Method for preparing 17 alpha-acetoxy-11 beta-(4-n,n-dimethylamin ophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
CN101014349A (en) * 2003-06-20 2007-08-08 病毒基因混和公司 Antiviral compositions and methods of using the same
CN103259027A (en) 2005-04-28 2013-08-21 普罗透斯数字保健公司 Pharma-informatics system
US20070105828A1 (en) * 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
JP2009508494A (en) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Compositions comprising receptor-binding protein (RAP) variants specific for proteins comprising CR and uses thereof
JP4382735B2 (en) 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 Neuropathic pain treatment
DE102005059222B4 (en) * 2005-12-08 2007-10-11 Bayer Schering Pharma Ag 11β-Benzaldoxime derivatives of D-homoestra-4,9-dien-3-ones
DK1991559T3 (en) 2006-02-17 2012-10-08 Janssen Pharmaceutica Nv Oxasteroid derivatives as selective progesterone receptor modulators
US20070270393A1 (en) * 2006-02-17 2007-11-22 Theresa Buckley Methods and compositions for modulation of sleep cycle
DE102006018888A1 (en) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Process for the preparation of 4- [17beta-methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-diene-11beta-yl] benzaldehyde (E) -oxime (asoprisnil)
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
EP3693376A1 (en) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Compositions for suppressing endometrial proliferation
KR20090105944A (en) * 2007-01-17 2009-10-07 레프로스 쎄라피우틱스 아이엔씨. Methods for improved stability of steroid derivatives
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
TWI539953B (en) 2008-04-28 2016-07-01 瑞波若斯治療學公司 Compositions and methods for treating breast cancer
PT2398500T (en) 2009-02-20 2019-06-14 2 Bbb Medicines B V Glutathione-based drug delivery system
TWI556839B (en) 2009-05-06 2016-11-11 研究室護膚股份有限公司 Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
DE102009034366A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034362A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034367A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034526A1 (en) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034525A1 (en) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102010007722A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
DE102010007719A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
EP2550288A1 (en) 2010-03-22 2013-01-30 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US11103514B2 (en) 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
DE102011004899A1 (en) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
JP6821582B2 (en) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Use of glucocorticoid receptor antagonists and somatostatin analogs to treat ACTH-secreting tumors
EP3277281B1 (en) 2015-03-30 2022-01-05 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN113797210A (en) 2015-05-18 2021-12-17 拜耳医药股份有限公司 Selective Progesterone Receptor Modulator (SPRM) regimens
WO2017027851A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6995757B2 (en) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ，インク． Inhibitor of glucocorticoid receptor
CN108699102A (en) * 2015-12-23 2018-10-23 欧瑞克制药公司 Glucocorticoid receptor inhibitor
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3523315B1 (en) * 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor
CN110099688A (en) * 2016-11-17 2019-08-06 赛途公司 Bone myohypertrophia inducer
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CN108070016B (en) * 2017-12-29 2020-07-07 广西万德药业有限公司 Cyclic utilization method of steroid epoxy isomer
AU2020367769B2 (en) 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
US20230358768A1 (en) 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
KR20220149828A (en) 2021-04-30 2022-11-09 삼성전자주식회사 Semiconductor devices
WO2023000135A1 (en) * 2021-07-19 2023-01-26 Context Biopharma Inc. Processes of making onapristone and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190796A (en) * 1963-04-25 1965-06-22 Upjohn Co Process for inhibiting the growth of micrococcus agilis with 11beta-hydroxy-11-(2-pyridylmethyl)-pregnane-3, 20-dione
FR2377417A1 (en) * 1977-01-13 1978-08-11 Roussel Uclaf NEW STEROID DERIVATIVES SUBSTITUTED IN 11B, AS WELL AS THEIR PREPARATION PROCESS
FR2377418A1 (en) * 1977-01-13 1978-08-11 Roussel Uclaf NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brevet nr. 2423486, FR, Int. Cl. C07 D 301/12; 1977 *

Also Published As

Publication number Publication date
DE19975073I2 (en) 2004-01-08
CA1193246A (en) 1985-09-10
FI820042L (en) 1982-07-10
US4634695A (en) 1987-01-06
AU550334B2 (en) 1986-03-20
PT74263A (en) 1982-02-01
ES517764A0 (en) 1983-12-01
EP0057115A3 (en) 1982-09-29
JPH0466879B2 (en) 1992-10-26
HU185158B (en) 1984-12-28
FI77872B (en) 1989-01-31
KR840000581A (en) 1984-02-25
NL300001I2 (en) 2000-08-01
FI77872C (en) 1989-05-10
US4519946A (en) 1985-05-28
MD207B1 (en) 1995-05-31
JPH0234958B2 (en) 1990-08-07
US4447424A (en) 1984-05-08
AU7929682A (en) 1982-07-15
AU579211B2 (en) 1988-11-17
EP0057115A2 (en) 1982-08-04
DE19975073I1 (en) 2000-03-09
US4386085A (en) 1983-05-31
BG60768B2 (en) 1996-02-29
DK166680B1 (en) 1993-06-28
EP0057115B1 (en) 1985-03-20
AU5123685A (en) 1986-04-17
ES508588A0 (en) 1983-04-16
NL300001I1 (en) 2000-04-03
ZA8231B (en) 1982-11-24
JPH01279897A (en) 1989-11-10
LT2618B (en) 1994-04-25
FR2497807A1 (en) 1982-07-16
KR870001936B1 (en) 1987-10-22
SU1447289A3 (en) 1988-12-23
GEP19960479B (en) 1996-07-22
ES8401498A1 (en) 1983-12-01
FR2497807B1 (en) 1983-07-29
DE3262580D1 (en) 1985-04-25
IE820044L (en) 1982-07-09
DK4082A (en) 1982-07-10
IE52595B1 (en) 1987-12-23
ES8305786A1 (en) 1983-04-16
JPS57168000A (en) 1982-10-16
SG45987G (en) 1987-11-13

Similar Documents

Publication Publication Date Title
MD207C2 (en) Method of steroid derivatives preparation
YU48666B (en) Mometason monohydrate furoate and method of preparation thereof
ES8706717A1 (en) Steroids and therapeutic compositions containing same.
KR860004918A (en) Method for preparing tricyclo compound
HUP9902471A2 (en) Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing the same
HUT37128A (en) Process for the production of dihydropyridazinone-derivatives, as well as of pharmaceutical preparations containing these derivatives as agent
MXPA02012921A (en) Novel $g(b crystalline form of perindopril tert butylamine salt, preparation method, and pharmaceutical compositions containing same.
HUT71798A (en) Process for preparing pharmaceutical compositions of antidepressant activity containing 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol)
EG18548A (en) Process for preparing 13-halomilbemycin derivatives and compositions containing them
ES2036926A1 (en) (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists.
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
ATE148990T1 (en) MEDICINAL PRODUCTS CONTAINING EBASTIN OR EBASTIN ANALOGUES
AU7987587A (en) Quinoline base compound, process for the preparation thereof and anticancer agent containing the same as pharmacologically efficacious component
IL151488A0 (en) Method for the preparation of citalopram
HUP9902784A2 (en) Indan-1-ol compounds, process for their preparation and pharmaceutical compositions containing them
WO1999033825A8 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
NL179059C (en) PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT WITH ANTI-INFLAMMATORY EFFECTS, FORMED MEDICINAL PRODUCT AND METHOD FOR PREPARING MEDICINAL COMPOUNDS, SUITABLE FOR USE IN THIS PROCESS
HUP0100283A2 (en) Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same
ES8602712A1 (en) Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same.
EP0147181A3 (en) Thiazolylacetic acid derivatives and their preparation
KR860009035A (en) Preparation of 11-beta substituted steroids
KR930017874A (en) Derivatives of saturated nitrogen heterocycles
ES8602676A1 (en) Hexahydropyrrolo (2,1-a) isoquinoline derivatives.
HUP9801846A2 (en) 17-difluoromethylene-oestratrienes, use thereof medicaments containing them and process for production of compounds
ES8306481A1 (en) Cyclic sulfenamides, process for their preparation, medicines containing them and preparation of the latter.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20020109